{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:53:28Z","timestamp":1781880808244,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Development Fund, Macau SAR","award":["0075\/2024\/RIB2"],"award-info":[{"award-number":["0075\/2024\/RIB2"]}]},{"name":"Science and Technology Development Fund, Macau SAR","award":["0105\/2022\/A2"],"award-info":[{"award-number":["0105\/2022\/A2"]}]},{"name":"Science and Technology Development Fund, Macau SAR","award":["006\/2023\/SKL"],"award-info":[{"award-number":["006\/2023\/SKL"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04202-7","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:27:40Z","timestamp":1768264060000},"page":"2550-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic mechanisms and clinical translation of regorafenib combination therapies"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8531-8665","authenticated-orcid":false,"given":"Shaokui","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0734-9955","authenticated-orcid":false,"given":"Dayuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3236-9345","authenticated-orcid":false,"given":"Tong","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-3901","authenticated-orcid":false,"given":"Dongfan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5643-2085","authenticated-orcid":false,"given":"Kuanyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-1972","authenticated-orcid":false,"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3285-6827","authenticated-orcid":false,"given":"Yanchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-6981","authenticated-orcid":false,"given":"Wenzhe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"4202_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/CMAR.S88825","volume":"10","author":"G Goel","year":"2018","unstructured":"Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a \u201cme too\u2019\u2019 drug? Cancer Manag Res. 2018;10:425\u201337.","journal-title":"Cancer Manag Res"},{"issue":"18","key":"4202_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053\u201361.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245\u201355.","journal-title":"Int J Cancer"},{"issue":"3","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"H-D Kim","year":"2024","unstructured":"Kim H-D, Jung S, Lim HY, Ryoo B-Y, Ryu M-H, Chuah S, et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med. 2024;30(3):699\u2013707.","journal-title":"Nat Med"},{"issue":"1","key":"4202_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","volume":"25","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med. 2025;25(1):238.","journal-title":"Clin Exp Med"},{"issue":"9","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658\u201367.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4202_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1634\/theoncologist.2013-0059","volume":"19","author":"A Grothey","year":"2014","unstructured":"Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19(6):669\u201380.","journal-title":"Oncologist"},{"issue":"9","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40265-018-0932-4","volume":"78","author":"Y-A Heo","year":"2018","unstructured":"Heo Y-A, Syed YY. Regorafenib: a review in hepatocellular carcinoma. Drugs. 2018;78(9):951\u20138.","journal-title":"Drugs"},{"issue":"4","key":"4202_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102943","volume":"9","author":"M Caccese","year":"2024","unstructured":"Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, et al. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma. ESMO Open. 2024;9(4):102943.","journal-title":"ESMO Open"},{"issue":"11","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/bjc.2012.153","volume":"106","author":"D Strumberg","year":"2012","unstructured":"Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106(11):1722\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.iliver.2024.100092","volume":"3","author":"Z Li","year":"2024","unstructured":"Li Z, Zhong J, Zhang C, Zhang B, Shi X, Li L. Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: a real-world clinical study. iLIVER. 2024;3(2):100092.","journal-title":"iLIVER"},{"key":"4202_CR12","doi-asserted-by":"crossref","unstructured":"Yang F, Mao Y, Huang H, Luo W, Liu L, Chen W. The efficacy and safety of regorafenib\/fruquintinib combined with PD-1\/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies. Frontiers in Immunology. 2025 May 29;16:1579293.","DOI":"10.3389\/fimmu.2025.1579293"},{"issue":"9","key":"4202_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0308-1","volume":"51","author":"F Fondevila","year":"2019","unstructured":"Fondevila F, Mendez-Blanco C, Fernandez-Palanca P, Gonzalez-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med. 2019;51(9):1\u201315.","journal-title":"Exp Mol Med"},{"issue":"7","key":"4202_CR14","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ijc.32970","volume":"147","author":"S Juengpanich","year":"2020","unstructured":"Juengpanich S, Topatana W, Lu C, Staiculescu D, Li S, Cao J, et al. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: possible targets and future directions in the regorafenib era. Int J Cancer. 2020;147(7):1778\u201392.","journal-title":"Int J Cancer"},{"key":"4202_CR15","doi-asserted-by":"crossref","unstructured":"Liu J, Tao H, Yuan T, Li J, Li J, Liang H, et al. Immunomodulatory effects of regorafenib: enhancing the efficacy of anti-PD-1\/PD-L1 therapy. Front Immunol. 2022 Sep 2;13:992611","DOI":"10.3389\/fimmu.2022.992611"},{"issue":"7","key":"4202_CR16","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","volume":"12","author":"L Abou-Elkacem","year":"2013","unstructured":"Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013;12(7):1322\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"4202_CR17","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.7150\/thno.45363","volume":"10","author":"X Song","year":"2020","unstructured":"Song X, Shen L, Tong J, Kuang C, Zeng S, Schoen RE, et al. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Theranostics. 2020;10(18):8098\u2013110.","journal-title":"Theranostics"},{"issue":"10","key":"4202_CR18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/mc.70017","volume":"64","author":"L Zhu","year":"2025","unstructured":"Zhu L, Wang W, Dong Y, Han X, Zhang W, Zhang Z, et al. Venetoclax synergizes with regorafenib for colorectal cancer by targeting BCL-2. Mol Carcinog. 2025;64(10):1683\u201396.","journal-title":"Mol Carcinog"},{"key":"4202_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175986","volume":"957","author":"Y Yu","year":"2023","unstructured":"Yu Y, Wu T, Zhang X, Li P, Ye L, Kuang J, et al. Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells. Eur J Pharmacol. 2023;957:175986.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4202_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/etm.2022.11132","volume":"23","author":"ZY Chen","year":"2022","unstructured":"Chen ZY, Li J, Zhu SD, Li ZD, Yu JL, Wu J, et al. Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. Exp Ther Med. 2022;23(3):209.","journal-title":"Exp Ther Med"},{"key":"4202_CR21","doi-asserted-by":"crossref","unstructured":"Su C, Fennell LJ, Bond CE, Kane AM, Kerr G, Jard\u00e9 T, et al. Aspirin synergizes with regorafenib to reduce growth of colorectal cancer. bioRxiv. 2022 Feb 11:2022-02.","DOI":"10.1101\/2022.02.11.480021"},{"issue":"9","key":"4202_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s12094-019-02283-9","volume":"22","author":"B Wang","year":"2020","unstructured":"Wang B, Wang F, Ding A, Zhao H, Bu X. Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression. Clin Transl Oncol. 2020;22(9):1491\u20138.","journal-title":"Clin Transl Oncol"},{"key":"4202_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112661","volume":"147","author":"IT Chiang","year":"2022","unstructured":"Chiang IT, Lee YH, Tan ZL, Hsu FT, Tu HF. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomed Pharmacother. 2022;147:112661.","journal-title":"Biomed Pharmacother"},{"issue":"42","key":"4202_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406936121","volume":"121","author":"WL Ye","year":"2024","unstructured":"Ye WL, Huang L, Yang XQ, Wan S, Gan WJ, Yang Y, et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proc Natl Acad Sci USA. 2024;121(42):e2406936121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4202_CR25","doi-asserted-by":"publisher","first-page":"1631116","DOI":"10.3389\/fcell.2025.1631116","volume":"13","author":"G Agostini","year":"2025","unstructured":"Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, et al. Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids. Front Cell Dev Biol. 2025;13:1631116.","journal-title":"Front Cell Dev Biol"},{"key":"4202_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.18632\/oncotarget.28762","volume":"16","author":"L Booth","year":"2025","unstructured":"Booth L, Booth MR, Roberts JL, Yue Y, Kinsey E, Poklepovic A, et al. The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo. Oncotarget. 2025;16:662\u201378.","journal-title":"Oncotarget"},{"key":"4202_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2019.108227","volume":"74","author":"CS Wu","year":"2019","unstructured":"Wu CS, Wu SY, Chen HC, Chu CA, Tang HH, Liu HS, et al. Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. J Nutr Biochem. 2019;74:108227.","journal-title":"J Nutr Biochem"},{"issue":"2","key":"4202_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202205354","volume":"19","author":"W Jia","year":"2023","unstructured":"Jia W, Tian H, Jiang J, Zhou L, Li L, Luo M, et al. Brain-targeted HFn-Cu-REGO nanoplatform for site-specific delivery and manipulation of autophagy and cuproptosis in glioblastoma. Small. 2023;19(2):e2205354.","journal-title":"Small"},{"issue":"2","key":"4202_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/CAD.0000000000001549","volume":"35","author":"L Booth","year":"2024","unstructured":"Booth L, Roberts JL, Poklepovic A, Dent P. Autophagy as a therapeutic mechanism to kill drug-resistant cancer cells. Anticancer Drugs. 2024;35(2):177\u201382.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"4202_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115681","volume":"44","author":"J Chen","year":"2025","unstructured":"Chen J, Huang C, Mei J, Lin Q, Chen W, Tang J, et al. OTUD4 inhibits ferroptosis by stabilizing GPX4 and suppressing autophagic degradation to promote tumor progression. Cell Rep. 2025;44(5):115681.","journal-title":"Cell Rep"},{"key":"4202_CR31","doi-asserted-by":"publisher","first-page":"1586578","DOI":"10.3389\/fphar.2025.1586578","volume":"16","author":"M Raja Dahar","year":"2025","unstructured":"Raja Dahar M, Zhou S, Hu H, Lei J, Zeng K, Yu L. Synergistic effect of regorafenib with aminoglycosides in ferroptosis-mediated liver injury. Front Pharmacol. 2025;16:1586578.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4202_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41419-025-07772-0","volume":"16","author":"S Ye","year":"2025","unstructured":"Ye S, Chen J, Zheng Y, He M, Zhang Y, Cheng Y, et al. Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis. Cell Death Dis. 2025;16(1):448.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4202_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1692","volume":"14","author":"X Guan","year":"2024","unstructured":"Guan X, Liu R, Wang B, Xiong R, Cui L, Liao Y, et al. Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3\/GSDMD-mediated pyroptosis in colorectal cancer. Clin Transl Med. 2024;14(6):e1692.","journal-title":"Clin Transl Med"},{"key":"4202_CR34","doi-asserted-by":"crossref","unstructured":"Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC. The synergistic anti-cancer effects of NVP-BEZ235 and regorafenib in hepatocellular carcinoma. Molecules. 2020 May 25;25(10):2454.","DOI":"10.3390\/molecules25102454"},{"key":"4202_CR35","doi-asserted-by":"publisher","first-page":"1136114","DOI":"10.3389\/fphar.2023.1136114","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, Wu R, Wang W, Liu Y, Kong W, Yang B, et al. Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer. Front Pharmacol. 2023;14:1136114.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4202_CR36","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1007\/s11033-021-06715-0","volume":"48","author":"SM El-Hanboshy","year":"2021","unstructured":"El-Hanboshy SM, Helmy MW, Abd-Alhaseeb MM. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K\/Akt\/mTOR\/NF-$$\\kappa $$B and VEGF\/VEGFR2 signaling pathways. Mol Biol Rep. 2021;48(11):7233\u201342.","journal-title":"Mol Biol Rep"},{"key":"4202_CR37","doi-asserted-by":"crossref","unstructured":"Jeon Y, Kwon H, Chung T, Park YN, Sim J, Kim T, et al. Ginsenoside Rh3 enhances regorafenib efficacy in hepatocellular carcinoma by modulating FGFR4-STAT3-YAP signaling pathway. Biochemical Pharmacology. 2026 Jan 5:117679.","DOI":"10.1016\/j.bcp.2026.117679"},{"key":"4202_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2024.104319","volume":"49","author":"S Zhang","year":"2024","unstructured":"Zhang S, Zhang X, Ren Y, Huang L, Xu W, Wang H, et al. Regorafenib enhances the efficacy of photodynamic therapy in hepatocellular carcinoma through MAPK signaling pathway suppression. Photodiagn Photodyn Ther. 2024;49:104319.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"6","key":"4202_CR39","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/ijc.28669","volume":"135","author":"R Schmieder","year":"2014","unstructured":"Schmieder R, Hoffmann J, Becker M, Bhargava A, Muller T, Kahmann N, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135(6):1487\u201396.","journal-title":"Int J Cancer"},{"key":"4202_CR40","doi-asserted-by":"crossref","unstructured":"Bajbouj K, Qaisar R, Alshura MA, Ibrahim Z, Alebaji MB, Al Ani AW, et al. Synergistic anti-angiogenic effect of combined VEGFR kinase inhibitors, lenvatinib, and regorafenib: a therapeutic potential for breast cancer. Int J Mol Sci. 2022 Apr 16;23(8):4408.","DOI":"10.3390\/ijms23084408"},{"key":"4202_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102040","volume":"47","author":"D Ma","year":"2024","unstructured":"Ma D, Liu S, Liu K, He Q, Hu L, Shi W, et al. CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma. Transl Oncol. 2024;47:102040.","journal-title":"Transl Oncol"},{"issue":"4","key":"4202_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41419-022-04816-7","volume":"13","author":"YC Chang","year":"2022","unstructured":"Chang YC, Li CH, Chan MH, Chen MH, Yeh CN, Hsiao M. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. Cell Death Dis. 2022;13(4):391.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4202_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s41065-025-00517-1","volume":"162","author":"B Xu","year":"2025","unstructured":"Xu B, Liang X, Liu W, Wu B, Wang Q, Kai G, et al. EPHX1 enhances drug resistance to regorafenib by activating the JAK\/STAT signaling pathway in hepatocellular carcinoma cell lines. Hereditas. 2025;162(1):148.","journal-title":"Hereditas"},{"issue":"8","key":"4202_CR44","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1002\/ptr.7174","volume":"35","author":"T Yang","year":"2021","unstructured":"Yang T, Huo J, Xu R, Zhang Y. Synergistic effect of toosendanin and regorafenib against cell proliferation and migration by regulating WWOX signaling pathway in hepatocellular carcinoma. Phytother Res. 2021;35(8):4567\u201378.","journal-title":"Phytother Res"},{"key":"4202_CR45","doi-asserted-by":"crossref","unstructured":"Pai K-J, Chang Y, Chiang I-T, Hsu F-T. Abstract 6129: Investigate the mechanism and treatment efficacy of regorafenib combined with anti-PD-L1 on bladder cancer. Cancer Res. 2022;82(12_Supplement):6129.","DOI":"10.1158\/1538-7445.AM2022-6129"},{"key":"4202_CR46","unstructured":"Shek D, Akhuba L, Carlino MS, Nagrial A, Moujaber T, Read SA, et al. Immune-checkpoint inhibitors for metastatic colorectal cancer: a systematic review of clinical outcomes. Cancers (Basel). 2020 Jul;72(1):315-29."},{"issue":"6","key":"4202_CR47","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.1002\/cam4.5417","volume":"12","author":"WZ He","year":"2023","unstructured":"He WZ, Wang L, Yin CX, Yi JH, Jin YN, Jiang C, et al. Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. Cancer Med. 2023;12(6):6488\u201398.","journal-title":"Cancer Med"},{"key":"4202_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115111","volume":"213","author":"A Xiao","year":"2024","unstructured":"Xiao A, Li X, Wang C, Ye J, Fakih M. Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: a phase I nonrandomized clinical trial. Eur J Cancer. 2024;213:115111.","journal-title":"Eur J Cancer"},{"key":"4202_CR49","doi-asserted-by":"publisher","first-page":"1227644","DOI":"10.3389\/fonc.2023.1227644","volume":"13","author":"X Dai","year":"2023","unstructured":"Dai X, Ding W, He Y, Huang S, Liu Y, Wu T. Refractory microsatellite stable metastatic colorectal cancer with ERBB2\/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study. Front Oncol. 2023;13:1227644.","journal-title":"Front Oncol"},{"key":"4202_CR50","doi-asserted-by":"crossref","unstructured":"Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, et al. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. The Lancet. 2025 Nov 15;406(10517):2360-70.","DOI":"10.1016\/S0140-6736(25)02025-2"},{"key":"4202_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992455","volume":"12","author":"E Haque","year":"2022","unstructured":"Haque E, Muhsen IN, Esmail A, Umoru G, Mylavarapu C, Ajewole VB, et al. Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer. Front Oncol. 2022;12:992455.","journal-title":"Front Oncol"},{"issue":"1","key":"4202_CR52","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3892\/ol.2024.14451","volume":"28","author":"Z Li","year":"2024","unstructured":"Li Z, Wang J, Zhao J, Leng Z. Regorafenib plus programmed death-1 inhibitors vs. regorafenib monotherapy in second-line treatment for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Oncol Lett. 2024;28(1):318.","journal-title":"Oncol Lett."},{"issue":"4","key":"4202_CR53","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.21037\/jgo-24-468","volume":"15","author":"C Chen","year":"2024","unstructured":"Chen C, Luo X, Tang W, Geng H, Martinez-Perez J, Price T, et al. Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study. J Gastrointest Oncol. 2024;15(4):1497\u2013507.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"4202_CR54","first-page":"1","volume":"10","author":"M Toulmonde","year":"2025","unstructured":"Toulmonde M, Gu\u00e9gan J-P, Spalato-Ceruso M, Valentin T, Bahleda R, Peyraud F, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab. Signal Transduct Target Ther. 2025;10(1):1\u20139.","journal-title":"Signal Transduct Target Ther"},{"key":"4202_CR55","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.annonc.2025.05.351","volume":"36","author":"R Browne","year":"2025","unstructured":"Browne R, Cruz MIC, Bridgewater JA. 336P the use of regorafenib in cholangiocarcinoma: a real-world data (RWD) review. Ann Oncol. 2025;36:S131\u20132.","journal-title":"Ann Oncol"},{"issue":"9","key":"4202_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7236","volume":"13","author":"L Qiao","year":"2024","unstructured":"Qiao L, He W, Wang G, Chen H, Huang F, Zhang B, et al. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: a multicenter real-world study. Cancer Med. 2024;13(9):e7236.","journal-title":"Cancer Med"},{"key":"4202_CR57","doi-asserted-by":"crossref","unstructured":"Ou DL, Chen CW, Hsu CL, Chung CH, Feng ZR, Lee BS, et al. Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages. J Immunother Cancer. 2021 Mar 22;9(3):e001657.","DOI":"10.1136\/jitc-2020-001657"},{"key":"4202_CR58","doi-asserted-by":"crossref","unstructured":"Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020 Nov 24;8(2):e001435.","DOI":"10.1136\/jitc-2020-001435"},{"key":"4202_CR59","doi-asserted-by":"crossref","unstructured":"Pai K-J, Chiang I-T, Hsu F-T, Tsai J-J. Abstract 3282: regorafenib enhance PD-L1 expression via ATM activation and evaluate the therapeutic efficacy of combining PD-L1 antibody on bladder cancer. Cancer Res. 2023;83(7_Supplement):3282.","DOI":"10.1158\/1538-7445.AM2023-3282"},{"key":"4202_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114254","volume":"159","author":"L Xie","year":"2023","unstructured":"Xie L, Liu M, Cai M, Huang W, Guo Y, Liang L, et al. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-gamma\/NSDHL\/SREBP1\/TGF-beta1 axis in hepatocellular carcinoma. Biomed Pharmacother. 2023;159:114254.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4202_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383.","journal-title":"Cell Rep Med"},{"key":"4202_CR62","doi-asserted-by":"publisher","first-page":"1464610","DOI":"10.3389\/fmed.2024.1464610","volume":"11","author":"L Hu","year":"2024","unstructured":"Hu L, Shi W, Liu K, Ma D, Xin Q, Wang Z, et al. EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma. Front Med (Lausanne). 2024;11:1464610.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4202_CR63","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1038\/s41467-025-59588-3","volume":"16","author":"X Qu","year":"2025","unstructured":"Qu X, Hamidi H, Johnson RM, Sokol ES, Lin E, Eng C, et al. Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nat Commun. 2025;16(1):4332.","journal-title":"Nat Commun"},{"issue":"1","key":"4202_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.113956","volume":"436","author":"HM Zhou","year":"2024","unstructured":"Zhou HM, Chen DH, Diao WJ, Wu YF, Zhang JG, Zhong L, et al. Inhibition of RhoGEF\/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma. Exp Cell Res. 2024;436(1):113956.","journal-title":"Exp Cell Res"},{"issue":"10","key":"4202_CR65","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/ijc.34845","volume":"154","author":"V Lee","year":"2024","unstructured":"Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, et al. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer. 2024;154(10):1794\u2013801.","journal-title":"Int J Cancer"},{"key":"4202_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100684","volume":"52","author":"G Bai","year":"2025","unstructured":"Bai G, Zhao S, Zhao M, Chen L, Chen W. The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma. J Bone Oncol. 2025;52:100684.","journal-title":"J Bone Oncol"},{"key":"4202_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101274","volume":"82","author":"T Yang","year":"2025","unstructured":"Yang T, Zhang S, Nie K, Cheng C, Peng X, Huo J, et al. ZNF207-driven PRDX1 lactylation and NRF2 activation in regorafenib resistance and ferroptosis evasion. Drug Resist Update. 2025;82:101274.","journal-title":"Drug Resist Update"},{"issue":"1","key":"4202_CR68","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-022-12519-4","volume":"12","author":"F Ek","year":"2022","unstructured":"Ek F, Blom K, Selvin T, Rudfeldt J, Andersson C, Senkowski W, et al. Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci Rep. 2022;12(1):8943.","journal-title":"Sci Rep"},{"issue":"1","key":"4202_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-021-01034-0","volume":"14","author":"A Saeed","year":"2021","unstructured":"Saeed A, Park R, Sun W. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol. 2021;14(1):13.","journal-title":"J Hematol Oncol"},{"key":"4202_CR70","doi-asserted-by":"crossref","unstructured":"Bajpai P, Afaq F, Diffalha SA, Agarwal S, Kim HG, Otali D, et al. Abstract 585: regorafenib antitumor immune response is enhanced by a novel drug combination in CRC syngeneic model. Cancer Res. 2024;84(6_Supplement):585.","DOI":"10.1158\/1538-7445.AM2024-585"},{"issue":"1","key":"4202_CR71","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/10717544.2020.1815897","volume":"27","author":"Z Zhou","year":"2020","unstructured":"Zhou Z. Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care. Drug Deliv. 2020;27(1):1319\u201328.","journal-title":"Drug Deliv"},{"issue":"30","key":"4202_CR72","doi-asserted-by":"publisher","first-page":"42735","DOI":"10.1021\/acsami.5c07923","volume":"17","author":"X Shao","year":"2025","unstructured":"Shao X, Peng T, Yang C, Zhu J, Wang R, Yang L, et al. Ion-gradient driven drug-loading liposomes for codelivery of shikonin\/regorafenib for cancer immunometabolic therapy and postoperative intervention. ACS Appl Mater Interfaces. 2025;17(30):42735\u201350.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4202_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101955","volume":"33","author":"W Wang","year":"2025","unstructured":"Wang W, Sun C, Jing L, Xia Y, Zhang S, Shi Y. Light-driven secondary structural remodeling in biomimetic nanosystem to enhance tumor chemo-phototherapy. Mater Today Bio. 2025;33:101955.","journal-title":"Mater Today Bio"},{"key":"4202_CR74","doi-asserted-by":"crossref","unstructured":"Malik M, Ali Z, Khan S, Zeb A, Din Fu, Alamri AH, et al. TPGS-PLA nanomicelles for targeting lung cancer; synthesis, characterization, and in vitro antitumor efficacy. J Drug Deliv Sci Technol. 2024 Jan 1;91:105238.","DOI":"10.1016\/j.jddst.2023.105238"},{"key":"4202_CR75","doi-asserted-by":"crossref","unstructured":"Malik M, Anwar F, Dini L, Alamri AH, Al Fatease A, Lahiq AA, et al. Palbociclib- and regorafenib-loaded nanomicelles for the treatment of non-small cell lung cancer: pharmacokinetic and antitumor evaluations. J Pharmaceut Investig. 2025 Jun 20:1-21.","DOI":"10.1007\/s40005-025-00753-7"},{"key":"4202_CR76","doi-asserted-by":"crossref","unstructured":"Liu H, Yang N, Wang Y, Li T, Lu R. Precision design of ferritin nanocages: tumor-targeted delivery, multi-mechanism synergistic therapy and clinical translational challenges. Drug Dev Ind Pharm. 2025 Nov 3:1-7.","DOI":"10.1080\/03639045.2025.2582684"},{"key":"4202_CR77","doi-asserted-by":"publisher","first-page":"8481","DOI":"10.2147\/IJN.S518120","volume":"20","author":"L Song","year":"2025","unstructured":"Song L, Wu Y, Zhao S, Liu Y, Liu Z, Zhai Y, et al. ROS-responsive nanosystem targeted co-delivery YC-1 and regorafenib to alleviate hypoxia enhancing hepatocellular carcinoma therapy. Int J Nanomed. 2025;20:8481\u201396.","journal-title":"Int J Nanomed"},{"issue":"47","key":"4202_CR78","doi-asserted-by":"publisher","first-page":"64447","DOI":"10.1021\/acsami.4c10363","volume":"16","author":"N Peng","year":"2024","unstructured":"Peng N, Du Y, Liu J, Li D, Li Y, Deng K, et al. Injectable polydopamine nanoparticle-incorporated hydrogels for antiangiogenesis and stimulating tumoricidal immunity to inhibit metastasis and recurrence postresection. ACS Appl Mater Interfaces. 2024;16(47):64447\u201362.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"4202_CR79","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s43440-024-00570-z","volume":"76","author":"D Szkutnik-Fiedler","year":"2024","unstructured":"Szkutnik-Fiedler D, Szalek E, Otto F, Czyrski A, Karazniewicz-Lada M, Wolc A, et al. Pharmacokinetic interaction between regorafenib and atorvastatin in rats. Pharmacol Rep. 2024;76(5):1184\u201395.","journal-title":"Pharmacol Rep"},{"key":"4202_CR80","doi-asserted-by":"publisher","first-page":"1472896","DOI":"10.3389\/fphar.2025.1472896","volume":"16","author":"K Zhu","year":"2025","unstructured":"Zhu K, Xiong F, Bai H, Liu W. Case report: Pharmacokinetic interaction involving sirolimus and regorafenib in patients with post-transplant recurrent hepatocellular carcinoma. Front Pharmacol. 2025;16:1472896.","journal-title":"Front Pharmacol"},{"key":"4202_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine. 2023;58:101917.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"4202_CR82","first-page":"990","volume":"33","author":"Y Saito","year":"2025","unstructured":"Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatment. Support Care Cancer. 2025;33(11):990.","journal-title":"Support Care Cancer"},{"issue":"20","key":"4202_CR83","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/cancers17203316","volume":"17","author":"C Signorelli","year":"2025","unstructured":"Signorelli C, Basso M, Calegari MA, Anghelone A, Passardi A, Gallio C, et al. Real-world evidence of regorafenib dose escalation versus fixed dosing in refractory metastatic colorectal cancer: results from the ReTrITA study. Cancers. 2025;17(20):3316.","journal-title":"Cancers"},{"issue":"4","key":"4202_CR84","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/hep.31840","volume":"74","author":"JW Cheu","year":"2021","unstructured":"Cheu JW, Wong CC. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology. 2021;74(4):2264\u201376.","journal-title":"Hepatology"},{"key":"4202_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102999","volume":"139","author":"A Holz","year":"2025","unstructured":"Holz A, Paul B, Zapf A, Pantel K, Joosse SA. Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: a systematic review and meta-analysis. Cancer Treat Rev. 2025;139:102999.","journal-title":"Cancer Treat Rev"},{"key":"4202_CR86","doi-asserted-by":"crossref","unstructured":"Cremolini C, Cirac\u00ec P, Pietrantonio F, Lonardi S, Germani MM, Busico A, et al. Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): results of the phase II randomized PARERE trial by GONO. J Clin Oncol. 2025;43(17_suppl):LBA3515.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA3515"},{"issue":"1","key":"4202_CR87","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s12672-025-03481-4","volume":"16","author":"W Chen","year":"2025","unstructured":"Chen W, Zhou C, Liu G, Wang X, Yi Y, Xu Y, et al. PCK1 and ALDH1A1 are identified as biomarkers for inherent drug resistance in hepatocellular carcinoma. Discov Oncol. 2025;16(1):1626.","journal-title":"Discov Oncol"},{"issue":"19","key":"4202_CR88","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.3390\/cancers17193196","volume":"17","author":"RD Kim","year":"2025","unstructured":"Kim RD, Pan X, Zhang Y, Lunacsek O, Pisa F, Ostojic H, et al. Real-world study of patients with metastatic colorectal cancer and long-term response to regorafenib in the USA. Cancers. 2025;17(19):3196.","journal-title":"Cancers"},{"key":"4202_CR89","doi-asserted-by":"crossref","unstructured":"Okpalanwaka IF, Daugherity EA, McCormick AL, Anderson TS, Smith SL, Lawrence C, et al. A PD-L1\/CD3 bispecific antibody enhances the antitumor effects of regorafenib against colon cancer. Mol Cancer Ther. 2025 Aug 1;24(8):1240-1251.","DOI":"10.1158\/1535-7163.MCT-24-1015"},{"issue":"7","key":"4202_CR90","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.62347\/GMRV6636","volume":"15","author":"X Kong","year":"2025","unstructured":"Kong X, Bian J, Wang M, Zuo W, Tang Q, Sun M, et al. HER2-positive, RAS-mutant, MSS colorectal cancer: a rare subtype report and novel insights into immunotherapy and ADC combinations. Am J Cancer Res. 2025;15(7):3150.","journal-title":"Am J Cancer Res"},{"key":"4202_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708943","volume":"11","author":"NM Ayoub","year":"2021","unstructured":"Ayoub NM. Editorial: Novel combination therapies for the treatment of solid cancers. Front Oncol. 2021;11:708943.","journal-title":"Front Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04202-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04202-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:04:31Z","timestamp":1781877871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04202-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":91,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04202-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a review of previously published studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}